Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Amazon.com Inc (AMZN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Amazon.com Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.52 (market cap $5.07B), while Amazon.com Inc trades at $268.03 (market cap $2.94T). The key difference: Amazon.com Inc is far larger — about 579.9× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Amazon.com Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | AMZN | |
|---|---|---|
Market Cap | $5.07B | $2.94T |
Sector | Health | Consumer Cyclical |
52-Week High | $29.41 | $284.02 |
52-Week Low | $20.06 | $198.79 |
Enterprise Value | $4.19B | $3.04T |
Volume | — | 3,931,282 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.70, up 1.05% today, with a bullish technical trend and strong analyst support. The company reported robust Q2 2026 earnings, beating estimates with $0.18 EPS, and raised its 2026 revenue outlook. Revenue grew to $1.07 billion in 2025, with net income surging to $391 million, reflecting a 36.49% margin. Recent FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis adds to positive catalysts.
The outlook remains positive given earnings momentum and product sales growth, though high valuation multiples and recent negative cash flow pose risks. Analyst consensus targets $33.89, implying ~14% upside, with 70% recommending Buy. Key risks include clinical trial outcomes and competitive pressures in the biopharma sector.
Amazon (AMZN) trades at $267.84, down 3.69% over 24 hours, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals, including a 17.44% net income margin and robust revenue growth to $716.92 billion in 2025. Recent news highlights CEO Andy Jassy's optimistic outlook on AWS and AI chip expansion, fueling investor confidence.
Outlook remains positive with a consensus price target of $333.86, indicating 25% upside potential. Risks include intense competition in e-commerce and cloud services, alongside high capital expenditures. Wall Street sentiment is overwhelmingly bullish, with 89% of analysts rating it a buy, though volatility from macroeconomic factors warrants caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Amazon.com Inc
Amazon.com, Inc. is an online retailer that offers a wide range of products. The Company products include books, music, computers, electronics and numerous other products. Amazon offers personalized shopping services, Web-based credit card payment, and direct shipping to customers. Amazon also operates a cloud platform offering services globally.
Read more on AMZN →
